Correlation between Fecal Concentrations of Ciprofloxacin and Fecal Counts of Resistant Enterobacteriaceae in Piglets Treated with Ciprofloxacin: toward New Means To Control the Spread of Resistance?: CIPROFLOXACIN LEVELS AND RESISTANT BACTERIA IN FECES by Nguyen, Thu Thuy et al.
Correlation between Fecal Concentrations of
Ciprofloxacin and Fecal Counts of Resistant
Enterobacteriaceae in Piglets Treated with
Ciprofloxacin: toward New Means To Control the
Spread of Resistance?
Thu Thuy Nguyen, Elisabeth Chachaty, Clarisse Huy, Carole Cambier, Jean
De Gunzburg, France Mentre´, Antoine Andremont
To cite this version:
Thu Thuy Nguyen, Elisabeth Chachaty, Clarisse Huy, Carole Cambier, Jean De Gunzburg, et
al.. Correlation between Fecal Concentrations of Ciprofloxacin and Fecal Counts of Resistant
Enterobacteriaceae in Piglets Treated with Ciprofloxacin: toward New Means To Control the
Spread of Resistance?: CIPROFLOXACIN LEVELS AND RESISTANT BACTERIA IN FE-
CES. Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 2012, 56
(9), pp.4973-5. <10.1128/AAC.06402-11>. <inserm-00719159>
HAL Id: inserm-00719159
http://www.hal.inserm.fr/inserm-00719159
Submitted on 19 Jul 2012
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
  
1
Correlation between fecal concentrations of ciprofloxacin and fecal counts 1 
of resistant Enterobacteriaceae in piglets treated with ciprofloxacin: 2 
towards new means to control the spread of resistance?  3 
Thu Thuy Nguyen,
1,2† 
Elisabeth Chachaty,
3†§
 Clarisse Huy,
4
 Carole Cambier,
5
 Jean de 4 
Gunzburg,
4 
France Mentré
1,2,7
 and Antoine Andremont
1,6,7
   5 
1
University Paris Diderot, Sorbonne Paris Cité, Paris, France; 
2
INSERM, UMR 738, Paris, 6 
France ; 
3
Institut Gustave-Roussy, Paris, France; 
4
Da Volterra, Paris, France; 
5
University 7 
of Liège, Liège, Belgium;
 6
EA3964, “Emergence de la résistance bactérienne in vivo”, 8 
Paris, France; 
7
AP-HP, Hospital Bichat, Paris, France 9 
 10 
 11 
Running head 12 
CIPROFLOXACIN LEVELS AND RESISTANT BACTERIA IN FECES 13 
14 
                                                          
 
 
 
 
 
 
 
†
 The two authors contributed equally to the work. 
§ Corresponding author. Adresse: Service de Microbiologie Médicale, Département de Biologie et de Pathologie 
Médicale, Institut Gustave-Roussy, 114 rue Edouard-Vaillant, 94805 Villejuif, Paris, France. Phone: 33 (0)1 42 
11 52 34. Fax : 33 (0)1 42 11 44 01. E-mail: elisabeth.chachaty@igr.fr. 
This work was supported by a grant from DaVolterra.  
 
  
2
Abstract 15 
We assessed in a piglet model the relationship between fecal ciprofloxacin concentrations and 16 
ciprofloxacin resistant Enterobacteriaceae counts. Twenty-nine piglets were orally treated 17 
with placebo, ciprofloxacin 1.5 or 15 mg/kg/day from day D1 to D5. Areas under the curve 18 
(AUC) of concentrations increased sharply with dose and correlated positively with AUC of 19 
resistant bacteria log counts between D1 and D9. Removing residual colonic quinolones could 20 
help to control the emergence of resistance in fecal flora. 21 
22 
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Increasing resistance to fluoroquinolones in Gram-negative bacilli is of major concern 23 
because it compromises their therapeutic use (6, 7). Colonic flora is the reservoir of many of 24 
the Enterobacteriaceae species with clinical significance (2) which are exposed to antibiotic 25 
residues during fluoroquinolone treatments (9). It has been shown that administration of 26 
enrofloxacin, a fluoroquinolone used in animals, could promote the emergence of quinolone 27 
resistant enterobacteria in fecal flora of pigs (12). We also found that administration of oral 28 
ciprofloxacin is associated with the emergence of quinolone resistant strains of 29 
Enterobacteriaceae in fecal flora from human volunteers (3). However, rates of emergence of 30 
resistance were not significantly different although the volunteers were exposed to different 31 
antibiotic dosages. Of note, detection of resistance was only qualitative in that study, i.e. 32 
absence versus presence of detectable resistant bacteria, and not quantitative, expressing the 33 
densities of resistant bacteria in the feces. Indeed, several lines of evidence suggest that 34 
quantitative aspects of emergence of resistance should also be analyzed. For instance, in 35 
neutropenic patients, Gram-negative bacilli bacteremias are caused by the predominant fecal 36 
clone of this type (11). Also, the density of a given Escherichia coli strain in a subject’s fecal 37 
flora can influence to some extent its ability to cause urinary tract infection (8). In order to 38 
explore further the dynamics of fluoroquinolone resistance in the fecal flora during 39 
treatments, we assessed here in a prospective randomized study in piglets the relationship 40 
between fecal concentrations of ciprofloxacin and amounts of excreted ciprofloxacin resistant 41 
Enterobacteriaceae. 42 
Twenty-nine piglets from a single farm were included 4 weeks after birth. They were born 43 
from sows that were treated at the time of parturition with 2 g oxytetracycline given 44 
intramuscularly, but had not received directly any antimicrobials. Piglets were housed in 45 
individual boxes for 21 days before the start of treatment (D1) and were randomly assigned to 46 
oral treatment with placebo (9 piglets), ciprofloxacin 1.5 mg/kg/day (10 piglets) or 15 47 
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mg/kg/day (10 piglets) from D1 to D5. Ciprofloxacin suspension (Ciflox®, Bayer) or mineral 48 
water (placebo group) was administered once a day at least 4 hours before food to animals 49 
fasted for at least 12 hours. The protocol was approved by the local ethical committee. 50 
Fecal samples were recovered from piglets after anal stimulation on mornings before 51 
treatment (at D-1 and D1), during treatment (at D3 and D5, before ciprofloxacin 52 
administration), and after treatment (at D7 and D9). Samples were stored frozen at -80°C until 53 
microbiological analysis and ciprofloxacin assay were performed blinded of the treatment 54 
group. Fecal concentrations of ciprofloxacin were measured by microbiological assay (5) after 55 
ten-fold dilution in HCl 0.1N and then further dilutions in phosphate buffer pH 8.0. Counts of 56 
total and resistant Enterobacteriaceae were obtained after plating serial dilutions of fecal 57 
samples on Drigalski agar (BioRad laboratories, Marnes-la-Coquette, France) supplemented 58 
or not with 20 mg/l of nalidixic acid or with 2 mg/l of ciprofloxacin. However, since there 59 
was no significant differences in the counts obtained on the two types of media (data not 60 
shown), only counts on ciprofloxacin containing agar were used for further statistical analysis. 61 
Individual area under the curve (AUC) from D1 to D9 of ciprofloxacin fecal concentrations 62 
(AUC_CIP), of log counts (AUC_RES) and of percentages (AUC_%RES) of ciprofloxacin 63 
resistant Enterobacteriaceae above pre-treatment baseline values were computed by 64 
trapezoidal approach. These criteria were compared across groups by nonparametric ANOVA 65 
and pairwise Wilcoxon tests if global tests were statistically significant (with significance 66 
level at 0.05). All statistical analyses were performed using SAS 9.1 (SAS, Cary, NC). 67 
Concentrations of ciprofloxacin increased with the dose administered and peaked at 84.8±57.9 68 
versus 11.6±12.6 µg/g of feces at D5 in piglets treated with 15 and 1.5 mg/kg/day of 69 
ciprofloxacin respectively (p<0.001) (Fig. 1A). Fecal antibiotic activity was detectable to 70 
some extent in all animals 2 days after cessation of treatment (D7) but no activity was 71 
detected in any animal at D9. AUC_CIP was significantly higher for the group treated with 15 72 
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mg/kg/day of ciprofloxacin than that for the group treated with 1.5 mg/kg/day (p<0.0005) 73 
(Table 1).  74 
Most of the piglets (25/29, 86%) had ciprofloxacin resistant Enterobacteriaceae detected in 75 
fecal samples before treatment. Administration of ciprofloxacin promoted the increase of both 76 
absolute counts (Fig. 1B) and percentages of ciprofloxacin resistant enterobacteria (Fig. 1C) 77 
in the 2 treatment groups when compared with the placebo group. AUC_RES and 78 
AUC_%RES were significantly different between the groups treated with 1.5 mg/kg/day and 79 
15 mg/kg/day versus the placebo group (both p<0.01 for AUC_RES and both p<0.0005 for 80 
AUC_%RES). AUC_RES and AUC_%RES were also significantly higher for the group 81 
treated with 15 mg/kg/day than that for the group treated with 1.5 mg/kg/day (p<0.05 and 82 
p<0.001 respectively) (Table 1). 83 
There were significant correlations between AUC_CIP and AUC_RES as well as between 84 
AUC_CIP and AUC_%RES (both p<0.0001, Spearman tests). These relationships were 85 
adequately described using an Emax 86 
model:
AUC_CIPAUC_CIP
AUC_CIPAUC_RES
AUC_RESAUC_RES
+
×
+=
50
max
0  where AUC_RES0, 87 
AUC_RESmax and AUC_CIP50 are respectively the baseline, the maximal effect and the value 88 
of AUC_CIP to obtain 50% of the maximal effect (Fig. 2). 89 
We showed a significant positive correlation between the AUC of fecal ciprofloxacin 90 
concentrations and the AUC of log ciprofloxacin resistant Enterobacteriaceae counts from 91 
D1 of treatment to D9 post treatment. Rapid increase of ciprofloxacin resistant enterobacteria 92 
from the beginning of ciprofloxacin administration probably resulted from the selection of 93 
resistant bacteria which were already present in low counts before treatment in the fecal flora 94 
of most (86%) of our piglets. Indeed, in a previous study in human volunteers (3), only 6 of 95 
48 (12.5%) had quinolone resistant enterobacteria detected before treatment and the increased 96 
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prevalence of resistance was only observed after the end of the treatment without significant 97 
dose relationship. The piglet study described here was much more fitted to evidence 98 
pharmacokinetic/pharmacodynamic relationship since the doses varied by a factor of 10, 99 
starting from a very low dose to a clinical dose (from 1.5 to 15 mg/kg/day) whereas they only 100 
varied by a factor of 3 (250 mg twice/day to 750 mg twice/day) in the volunteers. Median 101 
ciprofloxacin fecal concentrations at steady state were also much lower in piglet than in 102 
human volunteers groups of treatment (7 and 73 versus 845 and 1938 µg/g of feces 103 
respectively). An increase in the percentage of ciprofloxacin resistant Bacteroides fragilis 104 
strains in feces of human-flora-associated mice treated with various doses of ciprofloxacin has 105 
been also reported as dose-related (10). However, our results differ from the absence of 106 
correlation between antibiotic dosage and the percentages of fecal quinolone resistant 107 
enterobacteria during treatment that was observed by others in pigs receiving several doses of 108 
enrofloxacin varying in a range of 1 to 6 (12). Dynamic of emergence of resistant bacteria is 109 
dependant of several parameters among which the concentrations of free and active antibiotic 110 
reaching the colonic flora, MICs of bacterial populations and barrier effects exerted in the 111 
colonic ecosystem. This may account for the nonlinear correlation between fecal antibiotic 112 
concentrations and level of resistant bacteria we observed and, also, for differences in results 113 
from similar studies. 114 
We used AUCs to characterize the fecal pharmacokinetic/pharmacodynamic relationship for 115 
ciprofloxacin, taking into consideration the whole time-course of concentrations and bacteria 116 
counts. We believe that AUCs of fecal counts are the most relevant end-points because they 117 
describe, better than single time point values, the total amount of resistant bacteria excreted, 118 
which is actually what one wants to decrease to control the spread of resistance.  119 
Indeed, the link we showed between intestinal concentration of ciprofloxacin and the amount 120 
of ciprofloxacin-resistant enterobacteria excreted by the animals may be of upmost 121 
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importance in the current context of the spread of bacterial resistance. It has been shown in a 122 
rat model that the administration of a compound consisting of activated charcoal entrapped 123 
within zinc-pectinate beads could remove residual colonic ciprofloxacin (4). Thus, if such a 124 
removal could be obtained in animals or humans receiving therapeutic doses of quinolones 125 
without impairing the pharmacokinetics of the drug in plasma, this would open new avenues 126 
within the scope of the recently signaled eco-evo drugs (1) to help to control of the emergence 127 
and spread of quinolone resistance in gut-originating Gram-negative bacteria. 128 
 129 
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TABLE 1. Descriptive statistics by treatment group on AUC of ciprofloxacin concentrations 169 
(AUC_CIP), AUC of log counts of ciprofloxacin resistant Enterobacteriaceae above baseline 170 
(AUC_RES)
a 
and AUC of percentages of Enterobacteriaceae resistant to ciprofloxacin 171 
(AUC_%RES). 172 
Treatment group 
Mean±SD 
Median (Range) 
AUC_CIP 
(µgday/g) AUC_RES (log CFUday/g) AUC_%RES (%day) 
Placebo 
(n=9) 
0 
0 
-1.3±5.3 
0.5 (-13.5-5.1) 
4.5±6.1 
0.9 (0.1-15.6) 
Ciprofloxacin 1.5mg/kg/day 
(n=10) 
44.0±32.2 
30.6 (10.1-113.5) 
7.6±6.2 
7.1 (-0.2-21.5) 
284.9±124.8 
261.8 (86.5-504.8) 
Ciprofloxacin 15mg/kg/day  
(n=10) 
362.5±179.8 
299.3 (191.2-711.5) 
14.7±7.6 
15.0 (-1.0-26.0) 
567.1±98.2 
568.0 (403.9-700.0) 
a Some values of AUC_RES are negative because of the normalisation by the baseline. 173 
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 174 
FIG. 1. Mean (and 95% confidence intervals) of ciprofloxacin concentrations (Panel A) and of log 175 
counts of ciprofloxacin resistant Enterobacteriaceae (Panel B) as well as of percentages of 176 
Enterobacteriaceae resistant to ciprofloxacin (Panel C) in fecal samples from piglets treated with 177 
placebo (n = 9), 1.5 mg/kg/day (n = 10) and 15 mg/kg/day (n = 10) of oral ciprofloxacin from day 1 to 178 
day 9. 179 
  
12
 180 
FIG. 2. Relationship between individual AUC of fecal concentrations of ciprofloxacin (AUC_CIP) 181 
versus AUC of log counts of fecal ciprofloxacin resistant Enterobacteriacae (AUC_RES) (Panel A) 182 
and versus AUC of percentages of ciprofloxacin resistant Enterobacteriacae (AUC_%RES) (Panel B) 183 
for 29 piglets in 3 treatment groups. Each symbol represents the AUC_CIP and AUC_RES or 184 
AUC_%RES values for one piglet. The black curve among the symbols is the mean curve predicted by 185 
the Emax model. 186 
